Ambresin, Gilles http://orcid.org/0000-0001-8983-8501
Leuzinger-Bohleber, Marianne http://orcid.org/0000-0002-2421-2564
Fischmann, Tamara http://orcid.org/0000-0003-3990-8174
Axmacher, Nikolai http://orcid.org/0000-0002-0475-6492
Hattingen, Elke http://orcid.org/0000-0002-8392-9004
Bansal, Ravi http://orcid.org/0000-0003-4394-8355
Peterson, Bradley S. http://orcid.org/0000-0001-5737-225X
Funding for this research was provided by:
University of Lausanne
Article History
Received: 13 October 2023
Accepted: 17 October 2023
First Online: 16 November 2023
Declarations
:
: <i>Ethics approval</i> For the main study (current protocol), the ethics committee in Frankfurt gave its approval on August 14<sup>th</sup>, 2023. In Los Angeles, the original protocol was amended to correspond to the German main study protocol and has been accepted by the local ethics committee on June 6<sup>th</sup>, 2023. In Lausanne, the ethic committee from the Canton de Vaud gave its approval for the similarly amended protocol on September 5th, 2023. As regards, the feasibility study, in Frankfurt, the ethics committee gave its approval for the pilot study on March 16<sup>th</sup>, 2020 and for the main study August 14<sup>th</sup>, 2023. In Los Angeles, the protocol has been accepted by the local ethics committee on June 10<sup>th</sup>, 2020. In Lausanne, the ethic committee from the Canton de Vaud gave its approval on February 18<sup>th</sup>, 2021.<i>Consent to participate</i> Patients and healthy controls signed an informed consent form in accordance with local law requirements.In the US site, the participant will also be given a copy of HIPAA, and Experimental Bill of Rights to read and sign in accordance with California State Law.
: Not applicable.
: The authors declare no competing interests.